source
- Carvykti shows 5-year survival in half of multiple myeloma patients in Phase 2 studyJohnson & Johnson and Legend Biotech reported that 10 of the 20 multiple myeloma patients treated with a single dose of Carvykti remained alive after a median follow‑up of 60.7 months, representing…
- Novo signs $1.3 billion deal with Nanexa to add long-acting injectables for obesity and diabetesNovo has entered a licensing agreement with Nanexa, valued at about 1.17 billion euros, to use Nanexa’s PharmaShell platform for its obesity and type‑2 diabetes medicines. The PharmaShell technolo…